Anticancer activity profiling of parthenolide analogs generated via P450-mediated chemoenzymatic synthesis

Publication date: Available online 8 August 2017
Source:Bioorganic & Medicinal Chemistry
Author(s): Hanan Alwaseem, Benjamin J. Frisch, Rudi Fasan
The plant-derived sesquiterpene lactone parthenolide (PTL) was recently found to possess promising anticancer activity but elaboration of this natural product scaffold for optimization of its pharmacological properties has proven challenging via available chemical methods. In this work, P450-catalyzed C–H hydroxylation of positions C9 and C14 in PTL was coupled to carbamoylation chemistry to yield a panel of novel carbamate-based PTL analogs ('parthenologs'). These compounds, along with a series of other C9- and C14-functionalized parthenologs obtained via O–H acylation, alkylation, and metal-catalyzed carbene insertion, were profiled for their cytotoxicity against a diverse panel of human cancer cell lines. These studies led to the discovery of several parthenologs with significantly improved anticancer activity (2-14 fold) compared to the parent molecule. Most interestingly, two PTL analogs with high cytotoxicity (LC50 ∼ 1-3 μM) against T cell leukemia (Jurkat), mantle cell lymphoma (Jeko-1), and adenocarcinoma (HeLa) cells as well as a carbamate derivative with potent activity (LC50 = 0.6 μM) against neuroblastoma cells (SK-N-MC) were obtained. In addition, these analyses resulted in the identification of parthenologs featuring both a broad spectrum and tumor cell-specific anticancer activity, thus providing valuable probes for the future investigation of biomolecular targets that can affect cell viability across multiple as well as specific types of human cancers. Altogether, these results highlight the potential of P450-mediated chemoenzymatic C–H functionalization toward tuning and improving the anticancer activity of the natural product parthenolide.

Graphical abstract

http://ift.tt/2fsuYSJ